Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04439825 · ClinicalTrials.gov registry record · Phase 1

Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction

A Phase 1 study of Mood, sponsored by DeNova Research.

Completed
Registry status
Phase 1
Development phase
45
Enrollment target
1
Study location

NCT04439825 is a Phase 1 study of Mood that has completed, run by DeNova Research. The registered enrollment target is 45 participants, below the 3,658-participant average among 29 other Mood trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04439825, a Phase 1 study of Mood, has completed, sponsored by DeNova Research.

COMPLETED
Registry status
Phase 1
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

Botox treatment into the upper one third of the face (glabella, forehead lines and/or lateral canthal lines) to analyze mood and self -appearance satisfaction in a Post Covid period on non-naïve Botox patients

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Botulinum Neurotoxin

Study Locations (1)

Illinois

  • DeNova Research - Chicago

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2020-07-20
Est. Completion 2020-12-01
Phase Phase 1

Sponsor

DeNova Research

18 total trials

What the Registry Record Tells You About NCT04439825

The ClinicalTrials.gov registry entry for NCT04439825 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,658-participant average among 29 other Mood trials with a reported enrollment target (99% lower). The listed sponsor is DeNova Research, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mood appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04439825 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT04439825 about?

NCT04439825 is a clinical study titled "Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction". Botox treatment into the upper one third of the face (glabella, forehead lines and/or lateral canthal lines) to analyze mood and self -appearance satisfaction in a Post Covid period on non-naïve Botox patients

What is the current status of trial NCT04439825?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2020-07-20. Estimated completion is 2020-12-01.

What conditions does trial NCT04439825 study?

This clinical trial studies the following conditions: Mood.

What interventions are being tested in trial NCT04439825?

The interventions under investigation include: Placebo (DRUG), Botulinum Neurotoxin (DRUG).

Who is sponsoring clinical trial NCT04439825?

This trial is sponsored by DeNova Research, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04439825 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mood

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.